Literature DB >> 8032660

Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

C Thollon1, C Cambarrat, J Vian, J F Prost, J L Peglion, J P Vilaine.   

Abstract

1. S 16257 is a new bradycardic agent. Its electropharmacological profile has been compared to that of the known bradycardic compound UL-FS 49 (Zatebradine). Intracellular recordings of action potentials (APs) were performed with conventional glass microelectrodes. 2. In the rabbit isolated sino-atrial node (SAN) tissue, S 16257 and UL-FS 49 (1 microM, 3 microM and 10 microM) were equipotent in slowing spontaneous APs firing predominantly by decreasing the rate of diastolic depolarization (at 3 microM, -23.8 +/- 3.9% and -27.9 +/- 2.6%, respectively). For the two compounds a maximal effect was obtained at 3 microM. In these preparations, action potential duration at 50% of total repolarization (APD50) was more affected by UL-FS 49 than S 16257 at any concentration tested (at 3 microM, +8.9 +/- 2.9% and +29.1 +/- 3.7% for S 16257 and UL-FS 49, respectively; P < or = 0.01). 3. To estimate the direct effects on AP duration, driven cardiac preparations were exposed to these agents. In guinea-pig papillary muscles, paced at a frequency of 1 Hz, increasing concentrations of S 16257 or UL-FS 49 (0.1 to 10 microM, 30 min exposure for each concentration) slightly prolonged AP repolarization. This prolongation was more marked for UL-FS 49 (at 1 microM, +6.1 +/- 0.6% and +11.2 +/- 1.3% elevation of APD50, for S 16257 and UL-FS 49, respectively). 4. Application of UL-FS 49 (3 microM) to rabbit Purkinje fibres, triggered at a frequency of 0.25 Hz, induced a marked prolongation of APD50 and APD90 (+149.4 +/- 51.2% and +86.0 +/- 15.4%, respectively). S 16257 (3 MicroM) induced only a weak prolongation of AP (+ 14.1 +/- 5.0% and + 14.8 +/- 3.3% for APD50 and APD90, respectively) significantly smaller than in the case of UL-FS 49.5. These results show that S 16257 slows the rate of spontaneous AP firing in isolated SAN mainly by a reduction of the diastolic depolarization of the cells, which suggests an inhibition of the pace-maker current (If). S 16257 and UL-FS 49 are equipotent in their bradycardic effect but S 16257 is more specific as it induces less increase in myocardial repolarization time.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032660      PMCID: PMC1910295          DOI: 10.1111/j.1476-5381.1994.tb13025.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Effects of heart rate on coronary flow and cardiac oxygen consumption.

Authors:  D LAURENT; C BOLENE-WILLIAMS; F L WILLIAMS; L N KATZ
Journal:  Am J Physiol       Date:  1956-05

2.  Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria.

Authors:  C Lillie; W Kobinger
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

Review 3.  Oxygen consumption of the heart. Newer concepts of its multifactoral determination.

Authors:  E H Sonnenblick; J Ross; E Braunwald
Journal:  Am J Cardiol       Date:  1968-09       Impact factor: 2.778

4.  Prolongation of the human cardiac monophasic action potential by sotalol.

Authors:  D S Echt; L E Berte; W T Clusin; R G Samuelsson; D C Harrison; J W Mason
Journal:  Am J Cardiol       Date:  1982-11       Impact factor: 2.778

5.  Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers.

Authors:  E Carmeliet
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

6.  Effects of pacing on triggered activity induced by early afterdepolarizations.

Authors:  B P Damiano; M R Rosen
Journal:  Circulation       Date:  1984-05       Impact factor: 29.690

7.  Effects of the bradycardic agent UL-FS 49 on exercise-induced regional contractile dysfunction in dogs.

Authors:  G Raberger; G Krumpl; W Schneider
Journal:  Int J Cardiol       Date:  1987-03       Impact factor: 4.164

8.  Can exercise-induced regional contractile dysfunction be prevented by selective bradycardic agents?

Authors:  G Krumpl; W Schneider; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

9.  Pharmacological influence of specific bradycardic agents on the pacemaker current of sheep cardiac Purkinje fibres. A comparison between three different molecules.

Authors:  P P Van Bogaert; M Goethals
Journal:  Eur Heart J       Date:  1987-12       Impact factor: 29.983

10.  Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".

Authors:  W Kobinger; C Lillie
Journal:  Eur J Pharmacol       Date:  1984-09-03       Impact factor: 4.432

View more
  52 in total

1.  Haemodynamic effects of the bacterial quorum sensing signal molecule, N-(3-oxododecanoyl)-L-homoserine lactone, in conscious, normal and endotoxaemic rats.

Authors:  S M Gardiner; S R Chhabra; C Harty; P Williams; D I Pritchard; B W Bycroft; T Bennett
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.

Authors:  Sebastian Nuding; Henning Ebelt; Robert S Hoke; Annette Krummenerl; Andreas Wienke; Ursula Müller-Werdan; Karl Werdan
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

3.  An updated computational model of rabbit sinoatrial action potential to investigate the mechanisms of heart rate modulation.

Authors:  Stefano Severi; Matteo Fantini; Lara A Charawi; Dario DiFrancesco
Journal:  J Physiol       Date:  2012-06-18       Impact factor: 5.182

4.  Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.

Authors:  Robinson Joannides; Nicholas Moore; Michaela Iacob; Patricia Compagnon; Guy Lerebours; Jean-François Menard; Christian Thuillez
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

5.  Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia.

Authors:  R Zhang; A Haverich; M Strüber; A Simon; M Pichlmaier; Christoph Bara
Journal:  Clin Res Cardiol       Date:  2008-07-21       Impact factor: 5.460

6.  Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening.

Authors:  L Lucats; B Ghaleh; P Colin; X Monnet; A Bizé; A Berdeaux
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

7.  New evidence for coupled clock regulation of the normal automaticity of sinoatrial nodal pacemaker cells: bradycardic effects of ivabradine are linked to suppression of intracellular Ca²⁺ cycling.

Authors:  Yael Yaniv; Syevda Sirenko; Bruce D Ziman; Harold A Spurgeon; Victor A Maltsev; Edward G Lakatta
Journal:  J Mol Cell Cardiol       Date:  2013-05-05       Impact factor: 5.000

8.  Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells.

Authors:  P Bois; J Bescond; B Renaudon; J Lenfant
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 9.  Preclinical results with I(f) current inhibition by ivabradine.

Authors:  Alain Berdeaux
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Heart rate and cardiovascular disease: an alternative to Beta blockers.

Authors:  Michael Liang; Aniket Puri; Gerard Devlin
Journal:  Cardiol Res Pract       Date:  2009-07-30       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.